Scout Bio to Present at Upcoming October Investor Conferences PHILADELPHIA, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Scout Bio, a biotechnology company focused on revolutionizing pet medicine by delivering a pipeline of one-time AAV gene therapies for major chronic...

Scout Bio Successfully Completes Pilot Clinical Study of SB-001, a Single-Injection AAV Gene Therapy for the Treatment of Feline CKD-Associated Anemia PHILADELPHIA, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Scout Bio today announced the successful completion of a CKD-associated anemia study in client owned cats treated with SB-001, an AAV expressing...